APO Research
Talk to an analyst

APO RESEARCH · REPORT

CXCR4 Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global CXCR4 Antagonists Market Analysis and Forecast 2026-2032

20 December 2025196 pages

Choose your research edition.

Industry ResearchCXCR4 Antagonists Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CXCR4 Antagonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal CXCR4 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CXCR4 Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal CXCR4 Antagonists Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global CXCR4 Antagonists market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for CXCR4 Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for CXCR4 Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for CXCR4 Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for CXCR4 Antagonists is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of CXCR4 Antagonists include Sanofi, Merck, Roche, Eli Lilly, X4 Pharmaceuticals, Upsher-Smith Laboratories, Harmonic Pharma, GlycoMimetics and BioLineRx, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for CXCR4 Antagonists, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of CXCR4 Antagonists, also provides the revenue of main regions and countries. Of the upcoming market potential for CXCR4 Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the CXCR4 Antagonists revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global CXCR4 Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for CXCR4 Antagonists revenue, projected growth trends, production technology, application and end-user industry.

CXCR4 Antagonists Segment by Company

Sanofi

Merck

Roche

Eli Lilly

X4 Pharmaceuticals

Upsher-Smith Laboratories

Harmonic Pharma

GlycoMimetics

BioLineRx

Biokine Therapeutics

CXCR4 Antagonists Segment by Type

USL311

Balixafortide (POL6326)

GMI-1359

BL-8040

Plerixafor (AMD3100)

Others

CXCR4 Antagonists Segment by Application

Chronic Inflammatory Diseases

HIV

Cancer

CXCR4 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CXCR4 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CXCR4 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CXCR4 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of CXCR4 Antagonists in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of CXCR4 Antagonists company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CXCR4 Antagonists revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global CXCR4 Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. USL311 Major Player Table 3. Balixafortide (POL6326) Major Player Table 4. GMI-1359 Major Player Table 5. BL-8040 Major Player Table 6. Plerixafor (AMD3100) Major Player Table 7. Others Major Player Table 8. Global CXCR4 Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Chronic Inflammatory Diseases Major Player Table 10. HIV Major Player Table 11. Cancer Major Player Table 12. CXCR4 Antagonists Industry Trends Table 13. CXCR4 Antagonists Industry Drivers Table 14. CXCR4 Antagonists Industry Opportunities and Challenges Table 15. CXCR4 Antagonists Industry Restraints Table 16. Global CXCR4 Antagonists Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global CXCR4 Antagonists Market Size by Region (2021-2026) & (US$ Million) Table 18. Global CXCR4 Antagonists Market Share by Region (2021-2026) Table 19. Global CXCR4 Antagonists Market Size by Region (2027-2032) & (US$ Million) Table 20. Global CXCR4 Antagonists Market Share by Region (2027-2032) Table 21. Global CXCR4 Antagonists Revenue by Players (US$ Million) & (2021-2026) Table 22. Global CXCR4 Antagonists Revenue Market Share by Players (2021-2026) Table 23. Global CXCR4 Antagonists Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global CXCR4 Antagonists Key Players Headquarters & Area Served Table 25. Global CXCR4 Antagonists Players, Product Type & Application Table 26. Global CXCR4 Antagonists Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global CXCR4 Antagonists by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global CXCR4 Antagonists Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global CXCR4 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 31. Global CXCR4 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 32. Global CXCR4 Antagonists Revenue Market Share by Type (2021-2026) Table 33. Global CXCR4 Antagonists Revenue Market Share by Type (2027-2032) Table 34. Global CXCR4 Antagonists Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global CXCR4 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 36. Global CXCR4 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 37. Global CXCR4 Antagonists Revenue Market Share by Application (2021-2026) Table 38. Global CXCR4 Antagonists Revenue Market Share by Application (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Sanofi CXCR4 Antagonists Product Portfolio Table 43. Sanofi Recent Development Table 44. Merck Company Information Table 45. Merck Business Overview Table 46. Merck CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Merck CXCR4 Antagonists Product Portfolio Table 48. Merck Recent Development Table 49. Roche Company Information Table 50. Roche Business Overview Table 51. Roche CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Roche CXCR4 Antagonists Product Portfolio Table 53. Roche Recent Development Table 54. Eli Lilly Company Information Table 55. Eli Lilly Business Overview Table 56. Eli Lilly CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Eli Lilly CXCR4 Antagonists Product Portfolio Table 58. Eli Lilly Recent Development Table 59. X4 Pharmaceuticals Company Information Table 60. X4 Pharmaceuticals Business Overview Table 61. X4 Pharmaceuticals CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio Table 63. X4 Pharmaceuticals Recent Development Table 64. Upsher-Smith Laboratories Company Information Table 65. Upsher-Smith Laboratories Business Overview Table 66. Upsher-Smith Laboratories CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio Table 68. Upsher-Smith Laboratories Recent Development Table 69. Harmonic Pharma Company Information Table 70. Harmonic Pharma Business Overview Table 71. Harmonic Pharma CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Harmonic Pharma CXCR4 Antagonists Product Portfolio Table 73. Harmonic Pharma Recent Development Table 74. GlycoMimetics Company Information Table 75. GlycoMimetics Business Overview Table 76. GlycoMimetics CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. GlycoMimetics CXCR4 Antagonists Product Portfolio Table 78. GlycoMimetics Recent Development Table 79. BioLineRx Company Information Table 80. BioLineRx Business Overview Table 81. BioLineRx CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. BioLineRx CXCR4 Antagonists Product Portfolio Table 83. BioLineRx Recent Development Table 84. Biokine Therapeutics Company Information Table 85. Biokine Therapeutics Business Overview Table 86. Biokine Therapeutics CXCR4 Antagonists Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Biokine Therapeutics CXCR4 Antagonists Product Portfolio Table 88. Biokine Therapeutics Recent Development Table 89. North America CXCR4 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 90. North America CXCR4 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 91. North America CXCR4 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 92. North America CXCR4 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 93. North America CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America CXCR4 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 95. North America CXCR4 Antagonists Revenue by Country (US$ Million) & (2027-2032) Table 96. Europe CXCR4 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 97. Europe CXCR4 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 98. Europe CXCR4 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 99. Europe CXCR4 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 100. Europe CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Europe CXCR4 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 102. Europe CXCR4 Antagonists Revenue by Country (US$ Million) & (2027-2032) Table 103. China CXCR4 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 104. China CXCR4 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 105. China CXCR4 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 106. China CXCR4 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia CXCR4 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 108. Asia CXCR4 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 109. Asia CXCR4 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 110. Asia CXCR4 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia CXCR4 Antagonists Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Asia CXCR4 Antagonists Revenue by Region (US$ Million) & (2021-2026) Table 113. Asia CXCR4 Antagonists Revenue by Region (US$ Million) & (2027-2032) Table 114. SAMEA CXCR4 Antagonists Revenue by Type (2021-2026) & (US$ Million) Table 115. SAMEA CXCR4 Antagonists Revenue by Type (2027-2032) & (US$ Million) Table 116. SAMEA CXCR4 Antagonists Revenue by Application (2021-2026) & (US$ Million) Table 117. SAMEA CXCR4 Antagonists Revenue by Application (2027-2032) & (US$ Million) Table 118. SAMEA CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. SAMEA CXCR4 Antagonists Revenue by Country (2021-2026) & (US$ Million) Table 120. SAMEA CXCR4 Antagonists Revenue by Country (US$ Million) & (2027-2032) Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. CXCR4 Antagonists Image Figure 2. Global CXCR4 Antagonists Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CXCR4 Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 4. USL311 Image Figure 5. Balixafortide (POL6326) Image Figure 6. GMI-1359 Image Figure 7. BL-8040 Image Figure 8. Plerixafor (AMD3100) Image Figure 9. Others Image Figure 10. Global CXCR4 Antagonists Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global CXCR4 Antagonists Market Size Share 2021 VS 2025 VS 2032 Figure 12. Chronic Inflammatory Diseases Image Figure 13. HIV Image Figure 14. Cancer Image Figure 15. Global CXCR4 Antagonists Market Size (US$ Million) & (2021-2032) Figure 16. Global CXCR4 Antagonists Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global CXCR4 Antagonists Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global CXCR4 Antagonists Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global CXCR4 Antagonists Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global CXCR4 Antagonists Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global CXCR4 Antagonists Revenue Market Share by Type (2021-2032) Figure 23. Global CXCR4 Antagonists Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global CXCR4 Antagonists Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global CXCR4 Antagonists Revenue Market Share by Application (2021-2032) Figure 26. North America CXCR4 Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America CXCR4 Antagonists Revenue Share by Type (2021-2032) Figure 28. North America CXCR4 Antagonists Revenue Share by Application (2021-2032) Figure 29. North America CXCR4 Antagonists Revenue Share by Country (2021-2032) Figure 30. United States CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe CXCR4 Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe CXCR4 Antagonists Revenue Share by Type (2021-2032) Figure 35. Europe CXCR4 Antagonists Revenue Share by Application (2021-2032) Figure 36. Europe CXCR4 Antagonists Revenue Share by Country (2021-2032) Figure 37. Germany CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China CXCR4 Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China CXCR4 Antagonists Revenue Share by Type (2021-2032) Figure 47. China CXCR4 Antagonists Revenue Share by Application (2021-2032) Figure 48. Asia CXCR4 Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia CXCR4 Antagonists Revenue Share by Type (2021-2032) Figure 50. Asia CXCR4 Antagonists Revenue Share by Application (2021-2032) Figure 51. Asia CXCR4 Antagonists Revenue Share by Region (2021-2032) Figure 52. Japan CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA CXCR4 Antagonists Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA CXCR4 Antagonists Revenue Share by Type (2021-2032) Figure 60. SAMEA CXCR4 Antagonists Revenue Share by Application (2021-2032) Figure 61. SAMEA CXCR4 Antagonists Revenue Share by Country (2021-2032) Figure 62. Brazil CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt CXCR4 Antagonists Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • USL311
  • Balixafortide (POL6326)
  • GMI-1359
  • BL-8040
  • Plerixafor (AMD3100)
  • Others
Applications
  • Chronic Inflammatory Diseases
  • HIV
  • Cancer
Companies covered
  • Sanofi
  • Merck
  • Roche
  • Eli Lilly
  • X4 Pharmaceuticals
  • Upsher-Smith Laboratories
  • Harmonic Pharma
  • GlycoMimetics
  • BioLineRx
  • Biokine Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 CXCR4 Antagonists Market by Type
  3. 1.2.1 Global CXCR4 Antagonists Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 USL311
  5. 1.2.3 Balixafortide (POL6326)
  6. 1.2.4 GMI-1359
  7. 1.2.5 BL-8040
  8. 1.2.6 Plerixafor (AMD3100)
  9. 1.2.7 Others
  10. 1.3 CXCR4 Antagonists Market by Application
  11. 1.3.1 Global CXCR4 Antagonists Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Chronic Inflammatory Diseases
  13. 1.3.3 HIV
  14. 1.3.4 Cancer
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 CXCR4 Antagonists Market Dynamics
  1. 2.1 CXCR4 Antagonists Industry Trends
  2. 2.2 CXCR4 Antagonists Industry Drivers
  3. 2.3 CXCR4 Antagonists Industry Opportunities and Challenges
  4. 2.4 CXCR4 Antagonists Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global CXCR4 Antagonists Market Perspective (2021-2032)
  2. 3.2 Global CXCR4 Antagonists Growth Trends by Region
  3. 3.2.1 Global CXCR4 Antagonists Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global CXCR4 Antagonists Market Size by Region (2021-2026)
  5. 3.2.3 Global CXCR4 Antagonists Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global CXCR4 Antagonists Revenue by Players
  2. 4.1.1 Global CXCR4 Antagonists Revenue by Players (2021-2026)
  3. 4.1.2 Global CXCR4 Antagonists Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global CXCR4 Antagonists Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global CXCR4 Antagonists Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global CXCR4 Antagonists Key Players Headquarters & Area Served
  7. 4.4 Global CXCR4 Antagonists Players, Product Type & Application
  8. 4.5 Global CXCR4 Antagonists Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global CXCR4 Antagonists Market CR5 and HHI
  11. 4.6.3 2025 CXCR4 Antagonists Tier 1, Tier 2, and Tier 3
5 CXCR4 Antagonists Market Size by Type
  1. 5.1 Global CXCR4 Antagonists Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global CXCR4 Antagonists Revenue by Type (2021-2032)
  3. 5.3 Global CXCR4 Antagonists Revenue Market Share by Type (2021-2032)
6 CXCR4 Antagonists Market Size by Application
  1. 6.1 Global CXCR4 Antagonists Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global CXCR4 Antagonists Revenue by Application (2021-2032)
  3. 6.3 Global CXCR4 Antagonists Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi CXCR4 Antagonists Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Merck
  8. 7.2.1 Merck Company Information
  9. 7.2.2 Merck Business Overview
  10. 7.2.3 Merck CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck CXCR4 Antagonists Product Portfolio
  12. 7.2.5 Merck Recent Developments
  13. 7.3 Roche
  14. 7.3.1 Roche Company Information
  15. 7.3.2 Roche Business Overview
  16. 7.3.3 Roche CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Roche CXCR4 Antagonists Product Portfolio
  18. 7.3.5 Roche Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly CXCR4 Antagonists Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 X4 Pharmaceuticals
  26. 7.5.1 X4 Pharmaceuticals Company Information
  27. 7.5.2 X4 Pharmaceuticals Business Overview
  28. 7.5.3 X4 Pharmaceuticals CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  29. 7.5.4 X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio
  30. 7.5.5 X4 Pharmaceuticals Recent Developments
  31. 7.6 Upsher-Smith Laboratories
  32. 7.6.1 Upsher-Smith Laboratories Company Information
  33. 7.6.2 Upsher-Smith Laboratories Business Overview
  34. 7.6.3 Upsher-Smith Laboratories CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio
  36. 7.6.5 Upsher-Smith Laboratories Recent Developments
  37. 7.7 Harmonic Pharma
  38. 7.7.1 Harmonic Pharma Company Information
  39. 7.7.2 Harmonic Pharma Business Overview
  40. 7.7.3 Harmonic Pharma CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Harmonic Pharma CXCR4 Antagonists Product Portfolio
  42. 7.7.5 Harmonic Pharma Recent Developments
  43. 7.8 GlycoMimetics
  44. 7.8.1 GlycoMimetics Company Information
  45. 7.8.2 GlycoMimetics Business Overview
  46. 7.8.3 GlycoMimetics CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  47. 7.8.4 GlycoMimetics CXCR4 Antagonists Product Portfolio
  48. 7.8.5 GlycoMimetics Recent Developments
  49. 7.9 BioLineRx
  50. 7.9.1 BioLineRx Company Information
  51. 7.9.2 BioLineRx Business Overview
  52. 7.9.3 BioLineRx CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  53. 7.9.4 BioLineRx CXCR4 Antagonists Product Portfolio
  54. 7.9.5 BioLineRx Recent Developments
  55. 7.10 Biokine Therapeutics
  56. 7.10.1 Biokine Therapeutics Company Information
  57. 7.10.2 Biokine Therapeutics Business Overview
  58. 7.10.3 Biokine Therapeutics CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Biokine Therapeutics CXCR4 Antagonists Product Portfolio
  60. 7.10.5 Biokine Therapeutics Recent Developments
8 North America
  1. 8.1 North America CXCR4 Antagonists Revenue (2021-2032)
  2. 8.2 North America CXCR4 Antagonists Revenue by Type (2021-2032)
  3. 8.2.1 North America CXCR4 Antagonists Revenue by Type (2021-2026)
  4. 8.2.2 North America CXCR4 Antagonists Revenue by Type (2027-2032)
  5. 8.3 North America CXCR4 Antagonists Revenue Share by Type (2021-2032)
  6. 8.4 North America CXCR4 Antagonists Revenue by Application (2021-2032)
  7. 8.4.1 North America CXCR4 Antagonists Revenue by Application (2021-2026)
  8. 8.4.2 North America CXCR4 Antagonists Revenue by Application (2027-2032)
  9. 8.5 North America CXCR4 Antagonists Revenue Share by Application (2021-2032)
  10. 8.6 North America CXCR4 Antagonists Revenue by Country
  11. 8.6.1 North America CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America CXCR4 Antagonists Revenue by Country (2021-2026)
  13. 8.6.3 North America CXCR4 Antagonists Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe CXCR4 Antagonists Revenue (2021-2032)
  2. 9.2 Europe CXCR4 Antagonists Revenue by Type (2021-2032)
  3. 9.2.1 Europe CXCR4 Antagonists Revenue by Type (2021-2026)
  4. 9.2.2 Europe CXCR4 Antagonists Revenue by Type (2027-2032)
  5. 9.3 Europe CXCR4 Antagonists Revenue Share by Type (2021-2032)
  6. 9.4 Europe CXCR4 Antagonists Revenue by Application (2021-2032)
  7. 9.4.1 Europe CXCR4 Antagonists Revenue by Application (2021-2026)
  8. 9.4.2 Europe CXCR4 Antagonists Revenue by Application (2027-2032)
  9. 9.5 Europe CXCR4 Antagonists Revenue Share by Application (2021-2032)
  10. 9.6 Europe CXCR4 Antagonists Revenue by Country
  11. 9.6.1 Europe CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe CXCR4 Antagonists Revenue by Country (2021-2026)
  13. 9.6.3 Europe CXCR4 Antagonists Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China CXCR4 Antagonists Revenue (2021-2032)
  2. 10.2 China CXCR4 Antagonists Revenue by Type (2021-2032)
  3. 10.2.1 China CXCR4 Antagonists Revenue by Type (2021-2026)
  4. 10.2.2 China CXCR4 Antagonists Revenue by Type (2027-2032)
  5. 10.3 China CXCR4 Antagonists Revenue Share by Type (2021-2032)
  6. 10.4 China CXCR4 Antagonists Revenue by Application (2021-2032)
  7. 10.4.1 China CXCR4 Antagonists Revenue by Application (2021-2026)
  8. 10.4.2 China CXCR4 Antagonists Revenue by Application (2027-2032)
  9. 10.5 China CXCR4 Antagonists Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia CXCR4 Antagonists Revenue (2021-2032)
  2. 11.2 Asia CXCR4 Antagonists Revenue by Type (2021-2032)
  3. 11.2.1 Asia CXCR4 Antagonists Revenue by Type (2021-2026)
  4. 11.2.2 Asia CXCR4 Antagonists Revenue by Type (2027-2032)
  5. 11.3 Asia CXCR4 Antagonists Revenue Share by Type (2021-2032)
  6. 11.4 Asia CXCR4 Antagonists Revenue by Application (2021-2032)
  7. 11.4.1 Asia CXCR4 Antagonists Revenue by Application (2021-2026)
  8. 11.4.2 Asia CXCR4 Antagonists Revenue by Application (2027-2032)
  9. 11.5 Asia CXCR4 Antagonists Revenue Share by Application (2021-2032)
  10. 11.6 Asia CXCR4 Antagonists Revenue by Country
  11. 11.6.1 Asia CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia CXCR4 Antagonists Revenue by Country (2021-2026)
  13. 11.6.3 Asia CXCR4 Antagonists Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA CXCR4 Antagonists Revenue (2021-2032)
  2. 12.2 SAMEA CXCR4 Antagonists Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA CXCR4 Antagonists Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA CXCR4 Antagonists Revenue by Type (2027-2032)
  5. 12.3 SAMEA CXCR4 Antagonists Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA CXCR4 Antagonists Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA CXCR4 Antagonists Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA CXCR4 Antagonists Revenue by Application (2027-2032)
  9. 12.5 SAMEA CXCR4 Antagonists Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA CXCR4 Antagonists Revenue by Country
  11. 12.6.1 SAMEA CXCR4 Antagonists Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA CXCR4 Antagonists Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA CXCR4 Antagonists Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst